Aphria Inc (TSE:APH) was downgraded by research analysts at Canaccord Genuity from a “speculative buy” rating to a “hold” rating in a research note issued to investors on Thursday. They currently have a C$8.25 price objective on the stock, up from their previous price objective of C$7.00. Canaccord Genuity’s target price suggests a potential upside of 5.77% from the company’s previous close.

Separately, AltaCorp Capital reiterated a “speculative” rating on shares of Aphria in a report on Thursday, August 17th.

Aphria (TSE:APH) traded down 0.51% during midday trading on Thursday, reaching $7.80. The company had a trading volume of 2,205,478 shares. The stock has a 50-day moving average price of $6.06 and a 200 day moving average price of $6.11. The company has a market capitalization of $1.08 billion and a PE ratio of 780.00. Aphria has a 12-month low of $3.32 and a 12-month high of $8.77.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/12/aphria-inc-aph-lowered-to-hold-at-canaccord-genuity.html.

Aphria Company Profile

Aphria Inc produces, supplies, and sells medical cannabis in Canada. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders.

Receive News & Ratings for Aphria Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria Inc and related companies with MarketBeat.com's FREE daily email newsletter.